Comparable Effects of Ticagrelor and Clopidogrel Based on Platelet Aggregation Test in Patients with Acute Coronary Syndrome
DOI:
https://doi.org/10.37287/ijghr.v8i4.1743Keywords:
acute coronary syndrome, clopidogrel, platelet aggregation test, ticagrelorAbstract
Ticagrelor and clopidogrel are P2Y₁₂ receptor inhibitors commonly administered as part of dual antiplatelet therapy in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Although ticagrelor demonstrates a more rapid onset of action and stronger platelet inhibition than clopidogrel in pharmacodynamic studies, its superiority in routine clinical practice remains debated. This study aimed to compare the effects of ticagrelor and clopidogrel on platelet aggregation in ACS patients undergoing PCI. A cross-sectional comparative study was conducted involving 33 ACS patients who were consecutively recruited from patients undergoing PCI and receiving either ticagrelor or clopidogrel. Platelet aggregation was evaluated using light transmission aggregometry with adenosine diphosphate (ADP) as the agonist at concentrations of 1, 2, 5, and 10 µM. Differences in platelet aggregation between treatment groups were analyzed using the Mann–Whitney U test. No statistically significant differences in platelet aggregation were observed between the ticagrelor and clopidogrel groups at all ADP concentrations tested (all p > 0.05). These findings suggest comparable platelet inhibitory effects between both P2Y₁₂ inhibitors in ACS patients undergoing PCI. Ticagrelor and clopidogrel demonstrated similar platelet aggregation profiles, indicating comparable platelet reactivity under both treatment regimens in ACS patients undergoing PCI in real-world clinical settings.
References
Almendro-Delia, M., Blanco-Ponce, E., Carmona-Carmona, J., Arboleda Sánchez, J. A., Rodríguez Yáñez, J. C., Soto Blanco, J. M., Fernández García, I., Castillo Caballero, J. M., García-Rubira, J. C., & Hidalgo-Urbano, R. J. (2022). Comparative Safety and Effectiveness of Ticagrelor versus Clopidogrel in Patients With Acute Coronary Syndrome: An On-Treatment Analysis From a Multicenter Registry. Frontiers in Cardiovascular Medicine, 9. https://doi.org/10.3389/fcvm.2022.887748
Aluvilu, A., & Ferro, A. (2022). Role of platelet function testing in acute coronary syndromes: A meta-analysis. Open Heart, 9(2). https://doi.org/10.1136/openhrt-2022-002129
Alvitigala, B. Y., Gooneratne, L. V., Constantine, G. R., Wijesinghe, R. A. N. K., & Arawwawala, L. D. A. M. (2020). Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy. Pharmacology Research & Perspectives, 8(6). https://doi.org/10.1002/prp2.686
Bergmark, B. A., Mathenge, N., Merlini, P. A., Lawrence-Wright, M. B., & Giugliano, R. P. (2022). Acute coronary syndromes. In www.thelancet.com (Vol. 399). www.thelancet.com
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G. A., Dweck, M. R., Galbraith, M., Gilard, M., Hinterbuchner, L., Jankowska, E. A., Jüni, P., Kimura, T., Kunadian, V., Leosdottir, M., Lorusso, R., Pedretti, R. F. E., … Ibanez, B. (2023). 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal, 44(38), 3720–3826. https://doi.org/10.1093/eurheartj/ehad191
Doshi, P. (2024). Doubts over landmark heart drug trial: ticagrelor PLATO study. BMJ, q2550. https://doi.org/10.1136/bmj.q2550
Geravandi, M., Nourabi, M., Navabifar, S., Geravandi, M., Hooshanginezhad, Z., Zand, S., & Taheri, P. (2024). A comparison of the effects of ticagrelor and clopidogrel in patients with acute ST-segment elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials. BMC Pharmacology and Toxicology, 25(1), 93. https://doi.org/10.1186/s40360-024-00817-8
Gorog, D. A., & Geisler, T. (2020). Platelet Inhibition in Acute Coronary Syndrome and Percutaneous Coronary Intervention: Insights from the Past and Present. Thrombosis and Haemostasis, 120(4), 565–578. https://doi.org/10.1055/s-0040-1702920
Gulati, M., Levy, P. D., Mukherjee, D., Amsterdam, E., Bhatt, D. L., Birtcher, K. K., Blankstein, R., Boyd, J., Bullock-Palmer, R. P., Conejo, T., Diercks, D. B., Gentile, F., Greenwood, J. P., Hess, E. P., Hollenberg, S. M., Jaber, W. A., Jneid, H., Joglar, J. A., Morrow, D. A., … Shaw, L. J. (2021). 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/ SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. In Circulation (Vol. 144, Issue 22, pp. E368–E454). Lippincott Williams and Wilkins. https://doi.org/10.1161/CIR.0000000000001029
He, S., Lin, Y., Tan, Q., Mao, F., Chen, K., Hao, J., Le, W., & Yang, J. (2023). Ticagrelor Resistance in Cardiovascular Disease and Ischemic Stroke. Journal of Clinical Medicine, 12(3), 1149. https://doi.org/10.3390/jcm12031149
Herron, G. C., & Bates, E. R. (2024). Review of the Ticagrelor Trials Evidence Base. Journal of the American Heart Association, 13(11). https://doi.org/10.1161/JAHA.123.031606
Ibrahim, H., & Kleiman, N. S. (2017). Platelet pathophysiology, pharmacology, and function in coronary artery disease. In Coronary Artery Disease (Vol. 28, Issue 7, pp. 614–623). Lippincott Williams and Wilkins. https://doi.org/10.1097/MCA.0000000000000519
Khan, F., Abid, S. A., Jani, R., Iram, H. Z., Kaur Dhanjal, M., Chaudhari, S. S., Rauf, M. Q., & Hirani, S. (2025). Efficacy and Safety of Ticagrelor Versus Clopidogrel in Patients With Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Cureus. https://doi.org/10.7759/cureus.86107
Kottke-Marchant, K. (2009). Importance of platelets and platelet response in acute coronary syndromes. Cleveland Clinic Journal of Medicine, 76(SUPPL.1). https://doi.org/10.3949/ccjm.76.s1.01
Kumar, A., Arsal, S. A., Shafique, M. A., Mustafa, M. S., Haseeb, A., & Iqbal, U. (2024). Comparison between ticagrelor and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A systematic review and meta-analysis. Journal of Medicine, Surgery, and Public Health, 2, 100064. https://doi.org/10.1016/j.glmedi.2024.100064
Kutcher, S. A., Dendukuri, N., Dandona, S., Nadeau, L., & Brophy, J. M. (2025). Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes trial (TC4): a Bayesian pragmatic cluster randomized controlled trial. Canadian Medical Association Journal, 197(12), E309–E318. https://doi.org/10.1503/cmaj.241862
Lindstrom, M., DeCleene, N., Dorsey, H., Fuster, V., Johnson, C. O., LeGrand, K. E., Mensah, G. A., Razo, C., Stark, B., Turco, J. V., & Roth, G. A. (2022). Global Burden of Cardiovascular Diseases and Risks Collaboration, 1990-2021. Journal of the American College of Cardiology, 80(25), 2372–2425. https://doi.org/10.1016/j.jacc.2022.11.001
Lodhi, H., Bhat, K. G., Guleria, V. S., Pillai, R. K. J., Goel, R., Sharma, N., Sharma, A., & Sharma, V. (2024). Clopidogrel resistance and its effect on clinical outcomes in acute coronary syndrome. Indian Heart Journal. https://doi.org/10.1016/j.ihj.2024.07.003
Marxer, C. A., Hjemdahl, P., Carrero, J. J., & Fu, E. L. (2025). Comparative effectiveness and safety of dual antiplatelet therapy with ticagrelor vs. clopidogrel in older adults with acute coronary syndrome: a target trial emulation study. European Heart Journal - Cardiovascular Pharmacotherapy, 11(6), 500–508. https://doi.org/10.1093/ehjcvp/pvaf035
Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI). (2024). Pedoman Tata Laksana Sindrom Koroner Akut Edisi ke-5.
Rauf, M. A., Ziyad, M., Mahmood, N., Ullah, R., Ahmad, F., Ullah, I., & Shah, S. M. (2025). Evaluating the Safety and Efficacy of Ticagrelor vs. Clopidogrel Following Percutaneous Coronary Intervention in Chronic Coronary Disease. Cureus. https://doi.org/10.7759/cureus.77610
Rollini, F., Franchi, F., Singh, K., Cho, J., Bhatti, M., DeGroat, C., Hu, J., Aggarwal, N., Alobaidi, Z., Thano, E., Ferrante, E., Zenni, M. M., Bass, T. A., & Angiolillo, D. J. (2016). Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors. Thrombosis and Haemostasis, 116(12), 1060–1069. https://doi.org/10.1160/TH16-05-0377
Sanderson, N. C., Parker, W. A. E., & Storey, R. F. (2021). Ticagrelor: clinical development and future potential. Reviews in Cardiovascular Medicine, 22(2). https://doi.org/10.31083/j.rcm2202044
Sulianty, & Aman, A. K. (2011). Platelet Aggregation in Acute Coronary Syndrome. INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY, 17(3), 163–165.
Wadowski, P. P., Pultar, J., Weikert, C., Eichelberger, B., Lang, I. M., Koppensteiner, R., Panzer, S., & Gremmel, T. (2021). Comparison of Light Transmission Aggregometry With Impedance Aggregometry in Patients on Potent P2Y12 Inhibitors. Journal of Cardiovascular Pharmacology and Therapeutics, 26(3), 260–268. https://doi.org/10.1177/1074248420968706
Watanabe, A., Aikawa, T., Miyamoto, Y., Ueyama, H. A., Fujisaki, T., Shoji, S., Hosseini, K., Slipczuk, L., Briasoulis, A., Kampaktsis, P. N., Wiley, J., Secemsky, E. A., Iwagami, M., Tsugawa, Y., & Kuno, T. (2025). Ticagrelor Paradox: Systematic Review and Network Meta‐Analysis. Journal of the American Heart Association, 14(17). https://doi.org/10.1161/JAHA.125.041959
Xu, X., Na, K., Qiu, M., Yang, X., Qi, Z., Li, J., Xu, K., Wang, X., Li, Y., & Han, Y. (2025). Effectiveness of clopidogrel vs. ticagrelor based on the ABCD-GENE score in acute coronary syndrome patients following percutaneous coronary intervention. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1606327
Zhou, C., Zhang, M., Zhao, Z., Li, E., Zhao, Y., Luo, W., Zheng, K., Liu, Y., Yin, C., Zhang, X., Gao, H., Zhao, D., & Ma, C. (2025). Clopidogrel vs. ticagrelor in ST-elevation myocardial infarction complicated by cardiogenic shock undergoing primary PCI. Thrombosis Journal, 23(1), 38. https://doi.org/10.1186/s12959-025-00721-z
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Indonesian Journal of Global Health Research
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
